Drugs / IMP321
IMP321
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT04252768 | Jun 2023 → Jun 2025 | breast cancer | Immutep S.A.S. | Withdrawn | No outcome recorded |
| Phase 1 | NCT03252938 | Aug 2017 → Sep 2026 expected | lung adenocarcinoma, peritoneal carcinomatosis, urothelial carcinoma | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02676869 | Apr 2016 → Aug 2019 | melanoma | Immutep Limited | Completed | No outcome recorded |
| Phase 1 | NCT00732082 | Feb 2009 → Feb 2010 | pancreatic neoplasm | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT00349934 | Jul 2006 → Nov 2009 | breast cancer | Immutep S.A.S. | Completed | No outcome recorded |
| Phase 1 | NCT00351949 | Sep 2005 → Aug 2008 | renal cell carcinoma | Immutep S.A.S. | Completed | No outcome recorded |
| Phase 1 | NCT00324623 | Sep 2005 → Nov 2011 | cutaneous melanoma | Prof. Serge Leyvraz | Completed | No outcome recorded |
| Phase 1 | NCT00354861 | May → Nov 2005 | — | Immutep S.A.S. | Completed | No outcome recorded |
| Phase 1 | NCT00354263 | Apr → Sep 2005 | — | Immutep S.A.S. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01308294 | Jun 2010 → Apr 2014 | melanoma | Centre Hospitalier Universitaire Vaudois | Terminated | No outcome recorded |
| Phase 1/2 | NCT00365937 | Aug 2006 → Dec 2013 | cutaneous melanoma | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04811027 | Aug 2021 → Mar 2024 | head and neck squamous cell carcinoma | Immutep S.A.S. | Completed | No outcome recorded |
| Phase 2 | NCT03625323 | Feb 2019 → Jun 2022 | head and neck squamous cell carcinoma, non-small cell lung carcinoma | Immutep S.A.S. | Completed | No outcome recorded |
| Phase 2 | NCT02614833 | Dec 2015 → Mar 2020 | breast adenocarcinoma | Immutep S.A.S. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05747794 | May 2023 → Oct 2026 expected | breast carcinoma | Immutep S.A.S. | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMP321 | “The overall purpose of this research is to evaluate the safety and toxicity of an investigational medication, IMP321, in patients being treated with gemcitabine.” NCT00732082 ↗10“with IMP321 (ImmuFact)/ LAG-3Ig (Lymphocyte activation gene-3 immunoglobulin-like domains) as adjuvant/immunostimulant” NCT01308294 ↗ |
| Known as | eftilagimod alpha | “IMP321 (eftilagimod alpha)” NCT02614833 ↗ |
| Known as | ImmuFact | “with IMP321 (ImmuFact)/ LAG-3Ig (Lymphocyte activation gene-3 immunoglobulin-like domains) as adjuvant/immunostimulant” NCT01308294 ↗ |
| Known as | LAG-3Ig | “First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity.” PMID 20653948 ↗ Jul 20101“with IMP321 (ImmuFact)/ LAG-3Ig (Lymphocyte activation gene-3 immunoglobulin-like domains) as adjuvant/immunostimulant” NCT01308294 ↗ |
| Action | Activate | “mediates APC and then antigen-experienced memory CD8+ T cell activation” PMID 20653948 ↗ Jul 2010 |
| Modality | Protein / enzyme biologic | “IMP321 (LAG-3Ig fusion protein)” PMID 24726012 ↗ Apr 2014 |
| Route | Subcutaneous | “The study drug will be given by subcutaneous injection:” NCT00349934 ↗ |